Brief: Evommune Initiates Phase 2B Clinical Trial Of Mrgprx2 Inhibitor Evo756 In Migraine Prophylaxis
30/07/2026 13:08
BRIEF-Evommune Initiates Phase 2B Clinical Trial Of Mrgprx2 Inhibitor Evo756 In Migraine Prophylaxis July 30 (Reuters) - Evommune Inc EVMN.N:
EVOMMUNE INITIATES PHASE 2B CLINICAL TRIAL OF MRGPRX2 INHIBITOR EVO756 IN MIGRAINE PROPHYLAXIS
EVOMMUNE - TOP-LINE DATA FROM PHASE 2B TRIAL EXPECTED IN 2027
Source text: ID:nBw1MS8Dha
Further company coverage: EVMN.N
((Reuters.Briefs@thomsonreuters.com;))